8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Feb 25, 2026·SEC
MiMedx Group, Inc.(MDXG)Earnings, Financials & Key Ratios
MDXG•NASDAQ
$4.20
13.1× P/E·Price updated Jul 7, 2026
AboutMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.Show more
- Revenue$419M+20.0%
- EBITDA$79M+21.4%
- Net Income$49M+14.5%
- EPS (Diluted)0.32+14.3%
- Gross Margin82.56%-0.3%
- EBITDA Margin18.82%+1.1%
- Operating Margin15.26%-9.6%
- Net Margin11.6%-4.6%
- ROE21.61%-14.5%
MDXG Price & Volume
MiMedx Group, Inc. (MDXG) stock price & volume — 10-year historical chart
Loading chart...
Revenue Volatility Challenges Recent Margin Expansion Gains
Investment Thesis • Updated 2026Q1
VerdictNeutral: While the balance sheet is significantly de-risked with only $1.5M in total debt
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Deteriorating
Primary Risk:Medicare reimbursement policy shifts
Key Thesis Takeaways
- MiMedx has demonstrated a successful deleveraging strategy, reducing total debt from $48.1M in 2023Q4 to $1.5M in 2026Q1, which provides a robust liquidity buffer against sector-specific regulatory risks.
- However, the company's top-line remains highly sensitive to procurement cycles, evidenced by a 33.1% revenue contraction in 2026Q1 that severely pressured operating margins to -27.2%.
- Investors should monitor whether the company can stabilize its core wound care demand and restore the 80%+ gross margins observed throughout 2025 to justify its current 1.39 P/S valuation.
Verdict Logic
the 33.1% revenue contraction and negative operating margins of -27.2% in 2026Q1 suggest that the company's path to consistent profitability remains fragile.
MDXG Growth Metrics
MiMedx Group, Inc. (MDXG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.38%
5 Years11.02%
3 Years16.05%
TTM10.51%
Profit CAGR
10 Years5.13%
5 Years-
3 Years-
TTM-23.61%
EPS CAGR
10 Years2.1%
5 Years-
3 Years-
TTM-25.51%
Return on Capital
10 Years3.33%
5 Years12.36%
3 Years25.83%
Last Year25.72%
MDXG Recent Earnings
MiMedx Group, Inc. (MDXG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.05+28.6%
$0.07
Rev
$59M-10.3%
$66M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.14+55.6%
$0.09
Rev
$118M+10.6%
$107M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.15+114.3%
$0.07
Rev
$114M+6.4%
$107M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.10+66.7%
$0.06
Rev
$99M+5.7%
$93M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.05vs $0.07+28.6% | $59Mvs $66M-10.3% |
| Q1 2026 | Feb 25, 2026 | $0.14vs $0.09+55.6% | $118Mvs $107M+10.6% |
| Q4 2025 | Oct 29, 2025 | $0.15vs $0.07+114.3% | $114Mvs $107M+6.4% |
| Q3 2025 | Jul 30, 2025 | $0.10vs $0.06+66.7% | $99Mvs $93M+5.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for MiMedx Group, Inc. (MDXG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.20 | $623.98M | 13.13 | 19.99% | 11.6% | 21.61% | — | |
| $1.69 | $214.76M | -3.60 | — | — | -35.04% | — | |
| $4.32 | $310.89M | -4.60 | -38.1% | -61.93% | -15.09% | — | |
| $0.72 | $32.23M | -0.87 | 15.84% | -49.3% | -1344.47% | — | |
| $38.97 | $813.24M | 15.46 | 3.21% | 4.88% | 13.43% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
Compare MDXG vs Peers
MiMedx Group, Inc. (MDXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDXG SEC Filings & Documents
MiMedx Group, Inc. (MDXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MDXG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDXG Frequently Asked Questions
MiMedx Group, Inc. (MDXG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is MiMedx Group, Inc.'s revenue?
MiMedx Group, Inc. (MDXG) reported $389.4M in revenue for fiscal year 2025.
How fast is MiMedx Group, Inc. growing?
MiMedx Group, Inc. (MDXG) grew revenue by 20.0% over the past year. This is strong growth.
Is MDXG profitable?
Yes, MiMedx Group, Inc. (MDXG) is profitable, generating $30.7M in net income for fiscal year 2025 (11.6% net margin).
Dividend & Returns
What is MDXG's return on equity?
MiMedx Group, Inc. (MDXG) has a return on equity (ROE) of 21.6%. This is excellent, indicating efficient use of shareholder capital.
What is MiMedx Group, Inc.'s free cash flow?
MiMedx Group, Inc. (MDXG) generated $66.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.